No Data
No Data
Express News | [Large Shareholding Report] Resona Asset Management reported holding 5.73% of Ortz (260A.JP) shares.
Oltz [Lockup Release Schedule]
■Orts <260A> Estimated number of shares to be released: 6,616,400 shares (estimated) Release date: 2025/01/09 Target shareholders: Estimated shares East Ventures No. 2 Investment Limited Liability Partnership: 709,600 shares Katsuryoku Limited Liability Partnership: 37,200 shares JAFCO SV4 Shared Investment Limited Liability Partnership: 2,620,000 shares SBI AI & Blockchain Investment Limited Liability Partnership: 1,100,000 shares INTAGE Open
Featured stock: A growth newcomer engaged in personal AI.
Ortz <260A.T> is a promising growth stock that is gaining high expectations for rise in the New Year's market. The company primarily offers SaaS (Software as a Service) products, such as the AI (Artificial Intelligence) minutes-making tool "AI GIJIROKU", and is also gaining attention for its research in personal AI. It went public in October last year. Unlike many other AI-related stocks that focus on solution services, it primarily operates in SaaS, and there is an acceptance of its current performance being in the red.
January 6 [Today's Investment Strategy]
Provides solutions for management consulting, M&A advisory, management execution support, business revitalization, and more.
Stocks that moved the previous day part 2: Kyogoku Unyu, GMO Ad Partners, Ise Chemical, ETC.
Stock Name <Code> Closing Price on the 26th ⇒ Change from Previous Day Fuji HD <4676> 1767.5 -91.5 Concern over the ripple effect of magazine articles. Kioxia HD <285A> 1590 -7425 Favorable return selling after significant rebound in recent days. Seed <7743> 551 -36 Continuing the declining trend after recent sharp price increase. Istyle <3660> 448 -19 Pressured by short-term funds' profit-taking selling. Appier Group <4180> 1479 -21 A sense of completion in the rebound.
Emerging Markets Stock Digest: Synbio Pharmaceuticals continues to fall, Business Coach temporarily hits the upper limit.
＜4263＞ Susmed 582 +7 rebound. It was announced that the operation of a clinical trial system (SUSMED SDS) utilizing Blockchain Technology was started in a doctor-led clinical trial at the National Center of Neurology and Psychiatry. This clinical trial targets patients with myalgic encephalomyelitis/chronic fatigue syndrome, aiming to verify the efficacy and safety of Rituximab. Utilizing SUSMED SDS, it aims to reduce monitoring tasks and improve the quality and reliability of the data obtained.